渗出性年龄相关性黄斑变性患者接受抗血管内皮生长因子治疗三年及以上结局:当前结局综述
本综述汇总了11项研究报告的渗出性年龄相关性黄斑变性患者接受抗血管内皮生长因子(VEGF)治疗≥36个月的长期结局,分析视力、光学相干断层扫描及安全性变化。结果显示视力改善最大出现在治疗开始后第1至2年,长期视力变化因研究而异且似乎取决于治疗方案,建议采用持续给药并保持无液体间期以维持视力获益,长期使用未发现额外不良事件证据。
要点
- 抗VEGF治疗≥36个月视力变化不一,最大改善出现在治疗开始后第1至2年。
- 五项研究最终视力降至低于治疗前基线,三项回到基线,三项下降但仍高于基线。
- 有趋势显示玻璃体腔注射频率更高者视力维持更好,不良事件率与既往注册研究相似。
核心结论
- 现有长期抗VEGF治疗证据表明,随访超过36个月时病程变化不一,似乎取决于治疗方案。
- 建议采用持续给药并保持无液体间期以维持渗出性年龄相关性黄斑变性患者的视力获益。
- 无证据表明长期使用抗VEGF会产生额外不良事件。
研究设计与样本
- 综述纳入11项报告抗VEGF治疗≥36个月长期结局的研究,包括6项3期临床试验的前瞻性扩展研究和5项回顾性评估研究,分析视力、光学相干断层扫描及安全性发现。
主要发现
- 抗VEGF治疗的最大视力改善出现在治疗开始后第1至2年。
- 五项研究中视力最终降至低于患者治疗前初始基线;三项研究中视力最终回到患者基线;三项研究中视力下降但最终仍高于患者基线。
- 有趋势显示玻璃体腔注射频率更高者视力维持更好。
- 不良事件率与既往抗VEGF药物注册研究相似。
临床怎么用
- 作者建议采用持续给药并保持无液体间期以维持渗出性年龄相关性黄斑变性患者的视力获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To summarize the findings of long-term outcomes of anti-vascular endothelial growth factor (VEGF) therapy (≥36 months) in patients with exudative age-related macular degeneration. METHODS: Studies reporting long-term outcomes (≥36 months) of anti-VEGF therapy (n = 11) were identified and analyzed for changes in visual acuity (VA), optical coherence tomography, and safety findings. RESULTS: Six prospective extension studies of Phase 3 clinical trials and five retrospective evaluation studies were identified. The largest improvements in VA with anti-VEGF treatment were found in Years 1 to 2 after treatment initiation. In five studies, VA ultimately declined below patients' pretreatment initial baseline; in three studies, VA ultimately returned to patients' baseline; in three studies, VA decreased but ultimately remained improved over patients' baseline. There was a trend demonstrating that a higher frequency of intravitreous injections showed a better maintenance in VA. Rates of adverse events were similar to previous registration studies of anti-VEGF drugs. CONCLUSION: The body of evidence to date regarding long-term anti-VEGF treatment indicates a variable course at greater than 36 months follow-up and seems to be dependent on the treatment protocol. Consistent dosing with fluid-free interval is suggested to maintain VA gains in patients with exudative age-related macular degeneration. There is no evidence suggesting that there are additional adverse events from long-term anti-VEGF use.
引用
- Qin VL, Young J, Silva FQ, et al. OUTCOMES OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR THREE OR MORE YEARS: A Review of Current Outcomes. Retina. 2018. PMID: 28671895. doi:10.1097/IAE.0000000000001753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。